Our Programs
Pipeline
Pipeline

Overcoming the hurdles
presented by inherited retinal disease

ATSENA THERAPEUTICS’ programs include cutting-edge gene therapies for X-linked retinoschisis (XLRS), Leber congenital amaurosis 1 (LCA1), and MYO7A-associated Usher syndrome (USH1B). Our pipeline of proprietary assets is powered by adeno-associated virus (AAV) technologies engineered to overcome the unique hurdles presented by inherited retinal disease.

Robust Pipeline of First or Best-in-Class Gene Therapies

Program Indication Preclinical Ind-Enabling Phase 1/2 Pivotal
ATSN-201 X-linked Retinoschisis (XLRS)
ATSN-101 Leber Congenital Amaurosis (LCA1)
  • Phase 3 initiation
    planned for H2 2026
ATSN-301 Usher Syndrome (USH1B)
ATSN -401 Stargardt Disease (STGD)
ATSN-501 Undisclosed
ATSN-601 Undisclosed
= Atsena Program
= Partnered with Nippon Shinyaku in US and Japan
accessibility optionsAccessibility
Text Size
A
A